Key result
Hypertensive patients without diabetes receiving beta blockers had a 13.3% incidence of impaired glucose tolerance and 5% incidence of diabetes mellitus over four months, compared to 0% for both in patients receiving ARBs.
Why the study?
Does beta-blocker therapy compared to ARB therapy worsen blood glucose levels and increase the incidence of diabetes in hypertensive patients without diabetes?
Observational (n=85)
No
Does beta-blocker therapy compared to ARB therapy worsen blood glucose levels and increase the incidence of diabetes in hypertensive patients without diabetes?
Absolute Event Rate: 13.3% vs 0%
In Indian hypertensive patients without diabetes, beta-blocker therapy was associated with worsened glycemic control and an increased risk of new-onset impaired glucose tolerance and diabetes compared to ARB therapy.
Beta-blocker use was associated with glycemic worsening in nondiabetic hypertensives; hypothesis-generating versus ARBs and should not yet change practice.
Objective: There is highly co-incidence between hypertension and insulin resistance which is the important causative factor to develop diabetes mellitus (DM). There is paucity of data to establish the effect of beta-blockers and ARB on blood glucose level in Indian population. Therefore the present study was planned to search so that confederation among Indian population in a teaching hospital. Methods: The research study was carried out in 85 hypertensive patients without diabetes visiting the OPD of University teaching hospital (Majeedia hospital) New Delhi. Blood glucose levels and drug history of hypertensive patients were observed during four month of study. Results: The gender distribution of hypertensive patients reveals a higher percentage of incidences in males (53%) as compared to females (47%). Hypertensive patient without diabetes mellitus (DM) on beta blockers shows higher incidence of impaired glucose tolerance (IGT) (13.3%) and DM (5%) as compared to patient receiving ARBs as antihypertensive therapy. There was proportionate increase in incidence as the duration of therapy. None of the patients who were on angiotensin receptor blockers (ARBs) reported any incidence of IGT or DM. Conclusion: Beta blockers may be the risk factor to develop diabetes mellitus type 2 on long term use as an antihypertensive therapy. There were no any incidence of impaired glucose tolerance or diabetes mellitus found in case of patients taking ARBs as an antihypertensive therapy so it can be safely prescribe in hypertensive patients associated with diabetes mellitus type 2.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2013) conducted an observational in Hypertension without diabetes (n=85). Beta blockers vs. Angiotensin receptor blockers (ARBs) was evaluated on Incidence of impaired glucose tolerance (IGT). Hypertensive patients without diabetes receiving beta blockers had a 13.3% incidence of impaired glucose tolerance and 5% incidence of diabetes mellitus over four months, compared to 0% for both in patients receiving ARBs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: